Abstract
Poor pharmacokinetic and toxicity profiles are major reasons for the low rate of advancing lead drug candidates into efficacy studies. The In-silico prediction of primary pharmacokinetic and toxicity properties in the drug discovery and development process can be used as guidance in the design of candidates. In-silico parameters can also be used to choose suitable compounds for in-vivo testing thereby reducing the number of animals used in experiments. At the Novartis Institute for Tropical Diseases, a data set has been curated from in-house measurements in the disease areas of Dengue, Tuberculosis and Malaria. Volume of distribution, half-life, total in-vivo clearance, in-vitro human plasma protein binding and in-vivo oral bioavailability have been measured for molecules in the lead optimization stage in each of these three disease areas. Data for the inhibition of the hERG channel using the radio ligand binding dofetilide assay was determined for a set of 300 molecules in these therapeutic areas. Based on this data, Artificial Neural Networks were used to construct In-silico models for each of the properties listed above that can be used to prioritize candidates for lead optimization and to assist in selecting promising molecules for in-vivo pharmacokinetic studies.
Keywords: Neural Networks, computational ADME, computer aided drug design, molecular diversity, pharmacokinetics, mathematical models, molecular modeling.
Current Computer-Aided Drug Design
Title:Artificial Neural Network Analysis of Pharmacokinetic and Toxicity Properties of Lead Molecules for Dengue Fever, Tuberculosis and Malaria
Volume: 12 Issue: 1
Author(s): Shahul H. Nilar, Suresh B. Lakshminarayana, Ngai Ling Ma, Thomas H. Keller, Francesca Blasco and Paul W. Smith
Affiliation:
Keywords: Neural Networks, computational ADME, computer aided drug design, molecular diversity, pharmacokinetics, mathematical models, molecular modeling.
Abstract: Poor pharmacokinetic and toxicity profiles are major reasons for the low rate of advancing lead drug candidates into efficacy studies. The In-silico prediction of primary pharmacokinetic and toxicity properties in the drug discovery and development process can be used as guidance in the design of candidates. In-silico parameters can also be used to choose suitable compounds for in-vivo testing thereby reducing the number of animals used in experiments. At the Novartis Institute for Tropical Diseases, a data set has been curated from in-house measurements in the disease areas of Dengue, Tuberculosis and Malaria. Volume of distribution, half-life, total in-vivo clearance, in-vitro human plasma protein binding and in-vivo oral bioavailability have been measured for molecules in the lead optimization stage in each of these three disease areas. Data for the inhibition of the hERG channel using the radio ligand binding dofetilide assay was determined for a set of 300 molecules in these therapeutic areas. Based on this data, Artificial Neural Networks were used to construct In-silico models for each of the properties listed above that can be used to prioritize candidates for lead optimization and to assist in selecting promising molecules for in-vivo pharmacokinetic studies.
Export Options
About this article
Cite this article as:
Nilar H. Shahul, Lakshminarayana B. Suresh, Ma Ling Ngai, Keller H. Thomas, Blasco Francesca and Smith W. Paul, Artificial Neural Network Analysis of Pharmacokinetic and Toxicity Properties of Lead Molecules for Dengue Fever, Tuberculosis and Malaria, Current Computer-Aided Drug Design 2016; 12 (1) . https://dx.doi.org/10.2174/1573409912999160112113539
DOI https://dx.doi.org/10.2174/1573409912999160112113539 |
Print ISSN 1573-4099 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6697 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Activation of the Liver X Receptor Inhibits Th17 and Th1 Responses in Behcet`s Disease and Vogt-Koyanagi-Harada Disease
Current Molecular Medicine MIF and the Genetic Basis of Macrophage Responsiveness
Current Immunology Reviews (Discontinued) Eco-Friendly and Highly Efficient Synthesis, Including Multigram Synthesis, of Aldehyde Isonicotinoyl Hydrazones Using Sonochemistry
Letters in Organic Chemistry Prevalence of HIV Drug Resistance Mutation in the Northern Indian Population After Failure of the First Line Antiretroviral Therapy
Current HIV Research Design, Synthesis and Biological Evaluation of Novel Tetrahydroquinoline Based Propanehydrazides as Antitubercular Agents
Letters in Drug Design & Discovery Synthesis and Enzymological Characterization of Some 2-(Substitutedphenylamino) quinazolin-4(3H)-one Derivatives as Potent α-Glucosidase Inhibitors In Vitro
Letters in Drug Design & Discovery The Importance of NAD in Multiple Sclerosis
Current Pharmaceutical Design The Asymmetric Pictet – Spengler Reaction
Current Organic Synthesis On the Contribution of Molecular Topology to Drug Design and Discovery
Current Computer-Aided Drug Design Pharmacokinetic Properties and In Silico ADME Modeling in Drug Discovery
Medicinal Chemistry The Combined Effect of Curcumin and Crocin on the Reduction of Inflammatory Responses in Arthritic Rats
Current Medicinal Chemistry Synthesis, Characterization of (E)-N'-(substituted-benzylidene)isonicotinohydrazide Derivatives as Potent Antitubercular Agents
Letters in Drug Design & Discovery Heat Shock Proteins (HSPs) Based Anti-Cancer Vaccines
Current Molecular Medicine Marine Products with Anti-Protozoal Activity: A Review
Current Clinical Pharmacology Chemistry and Applications of 4-Hydroxyquinolin-2-one and Quinoline-2,4-dionebased Compounds
Current Organic Chemistry SCYPPred: A Web-Based Predictor of SNPs for Human Cytochrome P450
Protein & Peptide Letters Pathophysiology, Current Therapeutic Options, Vaccine Candidates, and Drug Targets for Human Brucellosis
Current Molecular Pharmacology New Approaches to Target the Mycolic Acid Biosynthesis Pathway for the Development of Tuberculosis Therapeutics
Current Pharmaceutical Design Comparative Proteome Analysis of <i>Mycobacterium Tuberculosis</i> Strains - H37Ra, H37Rv, CCDC5180, and CAS/NITR204: A Step Forward to Identify Novel Drug Targets
Letters in Drug Design & Discovery Synthesis and SAR Evaluation of Mercapto Triazolobenzothiazole Derivatives as Anti-tuberculosis Agents
Anti-Infective Agents